// App-Quantinova.ai

: Prognostic Impact of Germ-Line FCGR2A (H131R), FCGR3A (F158V), and FCGR2B (I232T) Single Nucleotide Polymorphisms in Lymphoma Patients Treated with Obinutuzumab or Rituximab in Combination with Chemotherapy: Results from the Phase III GALLIUM and GOYA Clinical Trials

Researchers

Presenter

  • Jonathan C Strefford

Principal Investigators

  • Chantal Hargreaves

  • Chisako Iriyama

  • Kate V Latham

  • Rosalind Ganderton

  • Helen Parker

  • Kathleen N Potter

  • Andrea Knapp

  • Farheen Mir

  • Matthew JJ Rose-Zerilli

  • Cathy Burton

  • Wolfgang Hiddemann

  • Wolfram Klapper

  • Laurie H Sehn

  • Umberto Vitolo

  • Maurizio Martelli

  • Marek Trnen

  • Andrew Davies

  • Mark C Cragg

  • Mikkel Z Oestergaard

Medical Centers

  • Cancer Sciences, University of Southampton, Southampton, United Kingdom

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

  • Southampton University Hospitals NHS Trust, Southhampton, United Kingdom

  • Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds, UK

  • Department of Neurosurgery, Ludwig-Maximilians University Munich, Munich, Germany

  • University of Kiel, Kiel, Germany

  • British Columbia Cancer Agency, Vancouver, BC, Canada

  • Department of Rheumatology, Azienda Ospedaliera Universitaria Citta della Salute e della Scienza di Torino, Turin, Italy,

  • Sapienza University, Rome, Italy

  • 1st Medical Department, Charles University General Hospital, Prague, Czech Republic

  • Cancer Sciences, University of Southampton, Southampton, United Kingdom

Locations

  • United Kingdom

  • Switzerland

  • Japan

  • Germany

  • Canada

  • Italy

  • Czech Republic

Companies

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lymphomas

Biomarkers

  • B-cell lymphoma 2

  • Fc gamma RIIIa

Drug/Treatment

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT01332968

  • NCT01287741

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved